MIRMMirum Pharmaceuticals, Inc.
$85.96+16% 1Y
$85.96
$64.1052 weeks$122.04
The financials
Mirum Pharmaceuticals, Inc. by the numbers
Mirum Pharmaceuticals, Inc. (MIRM) reported revenue of $176M in Q2 2026 (quarter ended Jun 30, 2026), up 38% from the same quarter a year earlier. That came with net loss of $67M. For the full year FY2025, revenue was $521M (+55% year on year) and net income −$23M. Its largest product in Q2 2026 was Livmarli at $129M, 73% of the disclosed total, well ahead of Bile Acid Medicines at 27%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $176M | $128M | +38% |
| Operating income | −$43M | −$5.0M | n/a |
| Net income | −$67M | −$5.9M | n/a |
| Diluted EPS | −$1.06 | −$0.12 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Livmarli | $129M | 73% |
| Bile Acid Medicines | $48M | 27% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $176.2M (+10%)
Livmarli grew +46% year on yearBile Acid Medicines +20% year on year
Segment Latestquarter on quarteryear on year
- Livmarli$128.7M$128.7Mquarter on quarter +13%year on year +46%+13%+46%
- Bile Acid Medicines$47.5M$47.5Mquarter on quarter +3.1%year on year +20%+3.1%+20%
On our screens:Most shorted stocks